Deutsche Bank AG Reiterates “$75.00” Price Target for Agilent Technologies, Inc. (A)

Deutsche Bank AG set a $75.00 target price on Agilent Technologies, Inc. (NYSE:A) in a research note released on Tuesday. The firm currently has a buy rating on the medical research company’s stock.

Other equities analysts have also recently issued reports about the company. Morgan Stanley reiterated an overweight rating on shares of Agilent Technologies in a research note on Tuesday, November 14th. Zacks Investment Research cut Agilent Technologies from a buy rating to a hold rating in a research note on Thursday, November 16th. Bank of America Corporation reiterated an equal weight rating on shares of Agilent Technologies in a research note on Tuesday, August 15th. BidaskClub cut Agilent Technologies from a strong-buy rating to a buy rating in a research note on Monday, July 31st. Finally, Goldman Sachs Group Inc reissued a neutral rating and set a $68.00 price target on shares of Agilent Technologies in a research report on Tuesday, September 26th. Five analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $68.34.

Agilent Technologies (NYSE A) opened at $69.36 on Tuesday. The firm has a market capitalization of $22,106.37, a P/E ratio of 28.98, a price-to-earnings-growth ratio of 2.07 and a beta of 1.27. Agilent Technologies has a fifty-two week low of $42.92 and a fifty-two week high of $70.81. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.30 and a quick ratio of 2.76.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Monday, November 20th. The medical research company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.05. The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. Agilent Technologies had a return on equity of 16.96% and a net margin of 15.30%. Agilent Technologies’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.59 EPS. equities analysts forecast that Agilent Technologies will post 2.58 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 24th. Shareholders of record on Tuesday, January 2nd will be given a $0.149 dividend. The ex-dividend date of this dividend is Friday, December 29th. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.13. This represents a $0.60 annualized dividend and a yield of 0.86%. Agilent Technologies’s dividend payout ratio (DPR) is currently 25.24%.

In related news, CEO Michael R. Mcmullen sold 16,492 shares of the firm’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $65.33, for a total transaction of $1,077,422.36. Following the completion of the transaction, the chief executive officer now owns 211,872 shares of the company’s stock, valued at $13,841,597.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Boon Hwee Koh sold 4,500 shares of the firm’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $63.63, for a total value of $286,335.00. The disclosure for this sale can be found here. Insiders sold 107,709 shares of company stock worth $7,195,576 over the last ninety days.

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in Agilent Technologies by 1.2% during the second quarter. BlackRock Inc. now owns 23,392,338 shares of the medical research company’s stock valued at $1,387,400,000 after buying an additional 273,119 shares in the last quarter. Vanguard Group Inc. boosted its stake in Agilent Technologies by 3.0% during the second quarter. Vanguard Group Inc. now owns 22,093,669 shares of the medical research company’s stock valued at $1,310,374,000 after buying an additional 637,698 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Agilent Technologies by 45.2% during the second quarter. JPMorgan Chase & Co. now owns 12,145,610 shares of the medical research company’s stock valued at $720,358,000 after buying an additional 3,779,099 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Agilent Technologies by 1.5% during the second quarter. Bank of New York Mellon Corp now owns 5,721,557 shares of the medical research company’s stock valued at $339,346,000 after buying an additional 84,801 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in Agilent Technologies by 5.5% during the second quarter. American Century Companies Inc. now owns 4,582,086 shares of the medical research company’s stock valued at $271,764,000 after buying an additional 238,522 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/11/25/deutsche-bank-ag-reiterates-75-00-price-target-for-agilent-technologies-inc-a.html.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply